Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale963
World Health Assembly ratifies first global diabetes targets890
A framework for improving diabetes care in humanitarian emergencies599
Mark Atkinson: bringing two worlds together527
Vitamin D to prevent acute respiratory infections519
What's preventing us from curbing the obesity crisis?419
Direct-to-consumer services: improving access to care for people with diabetes and obesity405
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p383
Better testing and labelling of drugs for people with obesity372
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98367
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2356
Type 1 diabetes screening: need for ethical, equity, and health systems perspective339
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality324
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?322
South Africa to produce insulin for Africa in 2024298
Anand Hardikar: a scientific nomad searching for the truth277
Implications of technology guidelines for low-income and middle-income countries248
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK245
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial242
A compass for navigating the perils of hypertriglyceridaemia195
Obesity in people living with type 1 diabetes194
Nutritional intake and bone health193
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions193
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial185
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials185
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial180
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses179
Jennifer Manne-Goehler: at the crossroads of pandemics168
The uncomfortable truth about kidney disease in type 1 diabetes161
The role of nurses in diabetes care: challenges and opportunities159
The promise and hope of GLP-1 receptor agonists154
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial153
What does renal failure teach us about our National Health System?151
A roadmap for integrating mental health and diabetes services131
Challenging diabetes stigma starts and ends with all of us128
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7127
Dapagliflozin in patients with COVID-19: truth or dare124
Putting wellbeing at the core of diabetes care123
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study123
Rising diabetes diagnosis in long COVID120
Glycaemic index as part of the diabetes prevention strategy118
Principles for virtual health care to deliver real equity in diabetes117
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing113
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin113
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply111
The changing character of diabetes complications108
Lebanon: insulin out of reach after subsidies lifted107
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss104
Explaining the high rate of progression from prediabetes to type 2 diabetes in China103
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials99
Childhood obesity: a growing pandemic97
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history96
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis94
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study92
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202091
Hypothalamic obesity: from basic mechanisms to clinical perspectives91
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors90
Improving HbA1c levels with advanced hybrid closed-loop therapy89
Women in diabetes research: stepping towards equity88
Is it time to re-assess the development of thyroid function reference ranges?85
Blood pressure control according to type 2 diabetes status84
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–1383
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international82
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1782
Glucagon, from past to present: a century of intensive research and controversies82
Male hypogonadism: pathogenesis, diagnosis, and management81
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 201980
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8377
Diabetes: knowing your risk matters76
Gender equality: timely and timeless76
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction74
Homing in on the causes of male infertility73
0.032165050506592